-DOCSTART- -X- O
Crimean-Congo -X- _ O
Haemorrhagic -X- _ O
Fever -X- _ O
( -X- _ O
CCHF -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
severe -X- _ O
tick-borne -X- _ O
disease -X- _ O
, -X- _ O
endemic -X- _ O
in -X- _ O
many -X- _ O
countries -X- _ O
in -X- _ O
Africa -X- _ O
, -X- _ O
the -X- _ O
Middle -X- _ O
East -X- _ O
, -X- _ O
Eastern -X- _ O
Europe -X- _ O
and -X- _ O
Asia. -X- _ O
Between -X- _ O
15â€“70 -X- _ O
% -X- _ O
of -X- _ O
reported -X- _ O
cases -X- _ O
are -X- _ O
fatal. -X- _ O
There -X- _ O
is -X- _ O
no -X- _ O
approved -X- _ O
vaccine -X- _ O
available -X- _ O
, -X- _ O
and -X- _ O
preclinical -X- _ O
protection -X- _ O
in -X- _ O
vivo -X- _ O
by -X- _ O
an -X- _ O
experimental -X- _ O
vaccine -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
demonstrated -X- _ O
previously. -X- _ O
In -X- _ O
the -X- _ O
present -X- _ O
study -X- _ O
, -X- _ O
the -X- _ O
attenuated -X- _ O
poxvirus -X- _ O
vector -X- _ O
, -X- _ O
Modified -X- _ O
Vaccinia -X- _ O
virus -X- _ O
Ankara -X- _ O
, -X- _ O
was -X- _ O
used -X- _ O
to -X- _ O
develop -X- _ O
a -X- _ O
recombinant -X- _ B-Intervention
candidate -X- _ I-Intervention
vaccine -X- _ I-Intervention
expressing -X- _ I-Intervention
the -X- _ I-Intervention
CCHF -X- _ I-Intervention
virus -X- _ I-Intervention
glycoproteins. -X- _ I-Intervention
Cellular -X- _ B-Outcome
and -X- _ I-Outcome
humoral -X- _ I-Outcome
immunogenicity -X- _ I-Outcome
was -X- _ I-Outcome
confirmed -X- _ I-Outcome
in -X- _ I-Outcome
two -X- _ I-Outcome
mouse -X- _ I-Outcome
strains -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
type -X- _ I-Outcome
I -X- _ I-Outcome
interferon -X- _ I-Outcome
receptor -X- _ I-Outcome
knockout -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
are -X- _ I-Outcome
susceptible -X- _ I-Outcome
to -X- _ I-Outcome
CCHF -X- _ I-Outcome
disease. -X- _ I-Outcome
This -X- _ I-Outcome
vaccine -X- _ I-Outcome
protected -X- _ I-Outcome
all -X- _ I-Outcome
recipient -X- _ I-Outcome
animals -X- _ I-Outcome
from -X- _ I-Outcome
lethal -X- _ I-Outcome
disease -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
challenge -X- _ I-Outcome
model -X- _ I-Outcome
adapted -X- _ I-Outcome
to -X- _ I-Outcome
represent -X- _ I-Outcome
infection -X- _ I-Outcome
via -X- _ I-Outcome
a -X- _ I-Outcome
tick -X- _ I-Outcome
bite. -X- _ I-Outcome
Histopathology -X- _ I-Outcome
and -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
analysis -X- _ I-Outcome
of -X- _ I-Outcome
protected -X- _ I-Outcome
animals -X- _ I-Outcome
confirmed -X- _ I-Outcome
that -X- _ I-Outcome
they -X- _ I-Outcome
had -X- _ I-Outcome
been -X- _ I-Outcome
exposed -X- _ I-Outcome
to -X- _ I-Outcome
challenge -X- _ I-Outcome
virus -X- _ I-Outcome
, -X- _ I-Outcome
even -X- _ I-Outcome
though -X- _ I-Outcome
they -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
exhibit -X- _ I-Outcome
clinical -X- _ I-Outcome
signs. -X- _ I-Outcome
This -X- _ O
is -X- _ O
the -X- _ O
first -X- _ B-Outcome
demonstration -X- _ I-Outcome
of -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
CCHF -X- _ I-Outcome
vaccine -X- _ I-Outcome
. -X- _ O

